A pooled analysis of phase III clinical trials and two endpoint trials showed aslightly elevated (but not significant) risk of pancreatitiswith GLP-1 receptor agonists (38 events, 17,775 patient-years of exposure) compared with the alternative treatment (nine events, 5,863 patient-years of ...
February 16, 2026 -The focus of this Review is on adverse events associated with the treatment with selective GLP-1RAs, or with thedual-targeted GIP receptor agonist (GIPRA)/GLP-1RA tirzepatide, the overall treatment uptake, adherence, and persistence of which have been suboptimal.
2 weeks ago -To investigate the genetic basis of this variability, here we conduct a genome-wide association study of self-reported weight loss and treatment-related side effects in 27,885 people following GLP1 receptor agonist therapy.
Such details provide a deeper understanding and appreciation for Glp1 Agonists With Disappointing Results.
November 21, 2022 -This is consistent with prior studies, and a system review reported that ADRs of GLP-1 RAs tend to arise from the gastrointestinal system, with nausea, diarrhea, and vomiting occurring in up to 51%, 20%, and 19% of patients, respectively (27). These gastrointestinal AEs are related to the inhibition effect of GLP1-RAs on delay in gastric emptying and stimulation of neural circuitry (9, 28, 29).
August 31, 2024 -This review investigates the side effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) likeliraglutide, semaglutide, and tirzepatide, medi…
